EW · NYSE
Consensus is $0.73 EPS for Sep 2026 across 9 estimates, ranging $0.72 to $0.75.
No consensus figures are available, so the quarter cannot be assessed against analyst expectations. Revenue increased 13.6% year over year to $1.7410 billion, but net income declined to $0.24 billion from $0.33 billion in Q2 FY2025. TAVR remained the largest contributor at $1,258.3 million, up 11.3%, while TMTT was the clear growth leader, rising 47.7% to $198.6 million. Surgical grew 6.5% to $284.1 million. Europe and Rest of World were the fastest-growing regions, up 16.2% and 19.3%, respectively, while Japan was nearly flat at 1.1%. Segment operating income increased to $1,061.6 million from $938.0 million, but consolidated profitability was pressured by a 53.6% effective tax rate versus 16.1% last year, including a $188.2 million valuation allowance. Foreign currency also reduced gross-margin percentage by 0.7 percentage points, despite lower manufacturing expenses.
No formal forward guidance for revenue, earnings, margins, or capital expenditures was given in the supplied material. Management said it expects Pillar Two provisions to create approximately $50.0 million of additional tax expense in 2026 before offsets under current law, with the expense potentially reduced as countries adopt the OECD Side-by-Side Safe Harbour. The company also warned that uncertain U.S. tariff rates could affect costs, customer demand, and results, and said it cannot predict the tariffs or whether mitigation efforts will succeed.
